International Myeloma Working Group Conference Series

Milan, Italy | June 11, 2014

 

Novel Agents and Best Treatment Choices for Transplant Eligible Patients

Novel Agents and Best Treatment Choices for Transplant-Ineligible Patients

What Are the Pros and Cons of Continuous Therapy?

Minimal Residual Disease (MRD): Can We Use the Information Clinically?

New Promising Therapies Presented at ASH/ASCO/IMWG/EHA

Measles Virotherapy